scholarly journals A Case for Enhancing Coverage of Influenza Vaccination in Gulf Cooperation Council Countries in Patients with Diabetes Mellitus during COVID-19

2021 ◽  
Vol 36 (6) ◽  
pp. e325-e325
Author(s):  
Salah T. Al Awaidy ◽  
Fatima Al Slail ◽  
Dalal Abdul Aziz Al Kathiry ◽  
Zayid K. Al Mayahi ◽  
Parvaiz A. Koul ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Influenza Vaccination ◽  
Gulf Cooperation Council ◽  
Patients With Diabetes

Nonspecific Immune Response Peculiarities to Influenza Vaccination in Patients with Diabetes Mellitus

2017 ◽  
Vol 2 (3) ◽  
pp. 43-47
Author(s):  
O. I. Grishyna ◽  
◽  
O. M. Babinets ◽  
O. V. Menkus ◽  
T. M. Myroshnychenko ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Immune Response ◽  
Influenza Vaccination ◽  
Patients With Diabetes ◽  
Nonspecific Immune Response

scholarly journals Glycaemic control, antidiabetic medications and influenza vaccination coverage among patients with diabetes in Udine, Italy

2019 ◽  
Vol 7 (3) ◽  
pp. e000198 ◽  
Author(s):  
Francesca Valent ◽  
Annarita Tullio
Keyword(s):  
Diabetes Mellitus ◽  
Glycaemic Control ◽  
Influenza Vaccination ◽  
Vaccination Coverage ◽  
Diabetes Management ◽  
University Hospital ◽  
Italian Population ◽  
Adjusted Relative Risk ◽  
Patients With Diabetes ◽  
Haemoglobin Testing

ObjectiveThe objectives of this study were to estimate influenza vaccination coverage among patients with diabetes mellitus in an Italian 250 000-inhabitant area in the 2017–2018 season and to assess whether glycaemic control and pharmacological treatment were associated with the likelihood of being vaccinated.DesignIn this cross-sectional study, we analysed anonymous health administrative databases, linked with each other at the individual patient level through a stochastic key: diabetes mellitus registry, vaccinations, drug prescriptions and laboratory database.SettingThe study was conducted in the catchment area of the University Hospital of Udine (‘the Udine area’), a 250 000-inhabitant area in the northeast of Italy.ParticipantsThe study included all subjects included in the regional registry of patients with diabetes mellitus, living in the Udine area as of 1 October 2017.Main outcome measuresVaccination coverage in the 2017–2018 influenza season was calculated. The association between patients’ characteristics and the likelihood of being vaccinated was assessed through multivariate log binomial regression.Result53.0% of 15 900 patients with diabetes living in the area were vaccinated. Coverage increased with age, approaching 75% at ≥85 years. Patients lacking recent glycated haemoglobin testing were less likely to be vaccinated (43.4% vaccination coverage), as were those not treated pharmacologically (44.4% vaccination coverage). Patients treated with both insulin, metformin and other antidiabetic medications were more likely to be vaccinated than those treated with metformin alone (58.1% vaccination coverage; adjusted relative risk=1.07, 95% CI 1.01 to 1.14).ConclusionInfluenza vaccination coverage was suboptimal in this Italian population of patients with diabetes. Strategies to improve diabetes management could in turn positively affect influenza coverage.

Intramuscular Nerve and Neuromuscular Junction Alteration In Extraocular Muscles of Diabetic Mice

1985 ◽  
Vol 43 ◽  
pp. 682-683
Author(s):  
Bruce R. Pachter
Keyword(s):  
Diabetes Mellitus ◽  
Peripheral Nerves ◽  
Sudden Onset ◽  
Extraocular Muscles ◽  
Diabetic Patients ◽  
Oculomotor Palsy ◽  
Third Nerve Palsy ◽  
Patients With Diabetes ◽  
Intramuscular Nerve ◽  
Oculomotor Nerves

Diabetes mellitus is one of the commonest causes of neuropathy. Diabetic neuropathy is a heterogeneous group of neuropathic disorders to which patients with diabetes mellitus are susceptible; more than one kind of neuropathy can frequently occur in the same individual. Abnormalities are also known to occur in nearly every anatomic subdivision of the eye in diabetic patients. Oculomotor palsy appears to be common in diabetes mellitus for their occurrence in isolation to suggest diabetes. Nerves to the external ocular muscles are most commonly affected, particularly the oculomotor or third cranial nerve. The third nerve palsy of diabetes is characteristic, being of sudden onset, accompanied by orbital and retro-orbital pain, often associated with complete involvement of the external ocular muscles innervated by the nerve. While the human and experimental animal literature is replete with studies on the peripheral nerves in diabetes mellitus, there is but a paucity of reported studies dealing with the oculomotor nerves and their associated extraocular muscles (EOMs).

Desmopressin Stimulates Parallel Norepinephrine and Tissue Plasminogen Activator Release in Normal Subjects and Patients with Diabetes Mellitus

1988 ◽  
Vol 59 (02) ◽  
pp. 269-272 ◽  
Author(s):  
M B Grant ◽  
C Guay ◽  
R Lottenberg
Keyword(s):  
Diabetes Mellitus ◽  
Plasminogen Activator ◽  
Tissue Plasminogen Activator ◽  
Time Course ◽  
Vascular Endothelial Cells ◽  
Normal Subjects ◽  
Plasma Norepinephrine ◽  
Endogenous Catecholamine ◽  
Tissue Plasminogen ◽  
Patients With Diabetes

SummaryDesmopressin acetate administration markedly stimulates release of tissue plasminogen activator (t-PA) from vascular endothelial cells. The mechanism for this effect is unknown. Because infusion of epinephrine has been shown to increase t-PA levels, we examined the role of endogenous catecholamine mediation of t-PA release by desmopressin. Intravenous desmopressin acetate (0.3 μg/kg) was infused over 30 min in 9 controls and 11 subjects with diabetes mellitus, a condition associated with abnormalities of the fibrinolytic system. Plasma was collected in the supine, overnight fasted state at 15 min intervals (0-60 min) for measurement of t-PA activity, t-PA antigen and fractionated catecholamines. t-PA activity peaked at 30-45 min and subsequently decreased. The norepinephrine levels paralleled the t-PA activity. t-PA activity increased 10-fold from 0.14 ± .12 to 1.49 ± 0.79 IU/ml (Mean ± SD) and plasma norepinephrine increased 2- fold from 426 ± 90 to 780 ± 292 pg/ml. However, epinephrine and dopamine levels did not change significantly. The response to desmopressin of control and diabetic subjects was not shown to differ and their data were combined. We conclude that desmopressin increases plasma norepinephrine in addition to t-PA and that the parallel time course of change suggests a possible role for norepinephrine in mediating endothelial cell t-PA release.

Sign in / Sign up

Export Citation Format

Share Document